Tech Company Financing Transactions
Invetx Funding Round
Invetx closed a $15 million Series A funding round on 2/25/2020. Investors included Anterra Capital and private investors.
Transaction Overview
Company Name
Announced On
2/25/2020
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
Anterra Capital (Lead Investor) (Philip Austin)
Proceeds Purpose
This financing will support rapid growth on multiple fronts, including bringing our first pet antibody therapeutic into clinical studies in 2020, expansion of our team and substantial preclinical development across our pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Boston Pl. 201 Washington St. 3930
Boston, MA 02108
USA
Boston, MA 02108
USA
Phone
Undisclosed
Website
Email Address
Overview
Invetx is building the world's premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts and veterinary scientists.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Juergen Horn
Chief Scientific Officer
William Brondyk
VP - Bus. Development
Colin Giles
Browse more venture capital transactions:
Prev: 2/25/2020: Pet Plate venture capital transaction
Next: 2/25/2020: Karius venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs